Target Name: LOC129026
NCBI ID: G129026
Review Report on LOC129026 Target / Biomarker Content of Review Report on LOC129026 Target / Biomarker
LOC129026
Other Name(s): gamma-glutamyltransferase-like activity 1 pseudogene | Gamma-glutamyltransferase-like activity 1 pseudogene

LOC129026: A Promising Drug Target and Biomarker for Diseases

LOC129026 is a gene that encodes a protein with gamma-glutamyltransferase-like activity. The protein is a key regulator of cellular processes that are essential for cell survival and growth, including cell division, apoptosis, and inflammation. Mutations in the LOC129026 gene have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, LOC129026 has emerged as a promising drug target and biomarker for a variety of diseases.

Location and Expression

LOC129026 is located on chromosome 16 at position 768.2. It is a member of the IMP (inositol-dependent protein kinase) family, which is characterized by the presence of a nucleotide-binding oligomerization domain (NBD) and a catalytic domain. The NBD is responsible for the transfer of inositol residues to target proteins, while the catalytic domain is responsible for the catalytic activity of the enzyme.

LOC129026 is predominantly expressed in the brain, with lower levels of expression found in other tissues. It is expressed in a variety of cell types, including neurons, glial cells, and immune cells. The protein is also expressed in the liver, as is common for genes that are involved in cellular processes that are important for liver function.

Function and Interaction

LOC129026 is a key regulator of gamma-glutamyltransferase (GGT), a enzyme that is involved in the transfer of glutamyl residues to a variety of proteins. GGT is a transmembrane protein that is located in the endoplasmic reticulum and is involved in a variety of cellular processes, including the regulation of protein synthesis, cell survival, and inflammation. LOC129026 is a critical regulator of GGT function, as it is able to inhibit the activity of GGT and prevent the transfer of glutamyl residues to other proteins.

LOC129026 is able to interact with a variety of other proteins, including GGT, GIPC (glutamyl-phosphatase and inhibitor of G protein-coupled receptor signaling), and NF-kappa-B (nuclear factor kappa B). These interactions are important for the regulation of cellular processes that are critical for cell survival and growth.

Disease association

Mutations in the LOC129026 gene have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, mutations in the LOC129026 gene have been associated with the development of neurobladder cancer, a type of cancer that is characterized by the formation of tumors in the neurobladder.

In addition, LOC129026 mutations have also been associated with a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These mutations have been shown to disrupt the regulation of cellular processes that are important for the survival and growth of neurons, leading to the development of neurodegeneration.

Furthermore, LOC129026 mutations have also been associated with autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These mutations have been shown to disrupt the regulation of cellular processes that are important for immune cell function, leading to the development of autoimmune disorders.

Drug targeting

LOC129026 is a drug target with potential for the treatment of a variety of diseases. One approach to targeting LOC129026 is to use small molecules that can inhibit the activity of GGT and prevent the transfer of glutamyl residues to other proteins. These small molecules can be used to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another approach to targeting LOC129026 is to use antibodies that recognize and label the protein. These antibodies can be used to diagnose and monitor the activity of LOC129026 in a variety of tissues and cells.

Biomarker potential

LOC129026 is also a potential biomarker for a variety of diseases. For example, LOC129026 mutations have been associated with the development of neurobladder cancer, a type of cancer that is characterized by the formation of tumors in the neurobladder. Therefore, LOC129026 could be used as a biomarker for neurobladder cancer.

LOC129026 mutations have also been associated with the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, LOC129026 could also be used as a biomarker for these diseases.

In addition, LOC129026 mutations have been associated with autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Therefore, LOC129026 could also be used as a biomarker for these diseases.

Conclusion

LOC129026 is a gene that encodes a protein with gamma-glutamyltransferase-like activity. The protein is a key regulator of cellular processes that are essential for cell survival and growth, including cell division, apoptosis, and inflammation. LOC129026 is predominantly expressed in the brain and is involved in the regulation of GGT function. Mutations in the LOC129026 gene have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, LOC129026 has emerged as a promising drug target and biomarker for a variety of diseases.

Protein Name: Gamma-glutamyltransferase-like Activity 1 Pseudogene

The "LOC129026 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC129026 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC132386 | LOC143666 | LOC145474 | LOC145845 | LOC148430 | LOC148696 | LOC149351 | LOC149684 | LOC151760 | LOC153893 | LOC153910 | LOC154449 | LOC154761 | LOC155060 | LOC157273 | LOC158434 | LOC158435 | LOC158696 | LOC162137 | LOC202181 | LOC221946 | LOC254896 | LOC260339 | LOC283028 | LOC283038 | LOC283045 | LOC283070 | LOC283194 | LOC283278 | LOC283299 | LOC283683 | LOC283731 | LOC283788 | LOC284009 | LOC284191 | LOC284240 | LOC284344 | LOC284379 | LOC284412 | LOC284581 | LOC284600 | LOC284788 | LOC284798 | LOC284898 | LOC284950 | LOC285097 | LOC285232 | LOC285626 | LOC285762 | LOC285819 | LOC285847 | LOC285889 | LOC286059 | LOC286083 | LOC286177 | LOC286297 | LOC286359 | LOC286437 | LOC338694 | LOC339059 | LOC339166 | LOC339260 | LOC339352 | LOC339593 | LOC339666 | LOC339685 | LOC339760 | LOC339975 | LOC340090 | LOC340184 | LOC340512 | LOC343052 | LOC344967 | LOC349160 | LOC374443 | LOC375196 | LOC387720 | LOC388242 | LOC388780 | LOC389199 | LOC389473 | LOC389765 | LOC389831 | LOC389834 | LOC389895 | LOC389906 | LOC390282 | LOC390705 | LOC391092 | LOC391343 | LOC391813 | LOC392180 | LOC392196 | LOC392232 | LOC399783 | LOC399900 | LOC400347 | LOC400464 | LOC400499 | LOC400541